FDA accelerates approval for Alzheimer’s drug

The Food and Drug Administration on Friday announced the fast-tracked approval of an Alzheimer’s drug that modestly slows the brain-robbing disease to those with mild impairment. The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory